Keywords
rheumatic disease
DMARDs
monoclonal antibodies
Categories
How to Cite
Abstract
Cytokines are small, secreted proteins that serve as the principal mediators of the immune system, orchestrating the complex interplay of cells involved in inflammation, immunity, and tissue homeostasis. Their dysregulation is a central feature in the pathophysiology of chronic inflammatory conditions, particularly autoimmune rheumatic diseases such as rheumatoid arthritis. This report provides a comprehensive, structured analysis of the history of cytokines, tracing their evolution from vaguely understood biological activities to precisely defined molecular targets for revolutionary therapies. To provide a conceptual foundation, fundamental definitions and classifications of cytokines are established, with a specific focus on how the core properties of pleiotropy, redundancy, and network complexity have profoundly influenced their study and therapeutic manipulation. The narrative subsequently details landmark discoveries of key pathogenic cytokines in rheumatology—including the TNF-α, IL-1, and IL-6 families—while detailing the paradigm shift prompted by the identification of the IL-23/Th17 axis. Parallel to these discoveries, the evolution of therapeutic agents is mapped from first-generation biologic disease-modifying anti-rheumatic drugs (bDMARDs), such as TNF inhibitors, to the oral revolution of targeted synthetic DMARDs like Janus kinase inhibitors, and onward to next-generation strategies including bispecific antibodies and engineered cytokines. In the final sections, the current state of the field is synthesized through a critical examination of unresolved questions and knowledge gaps, such as the mechanisms of treatment non-response, the challenge of cytokine redundancy, and the optimal management of systemic comorbidities. Prospective future directions are outlined, emphasizing an increasing focus on biomarker-driven patient stratification, multi-target combination strategies, and the ultimate pursuit of immune tolerance and curative therapies. Together, these developments represent a clear evolutionary trajectory toward the realization of precision medicine in rheumatology.
References
1. Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: From clinical significance to quantification. Adv Sci (Weinh) [Internet]. 2021 Aug;8(15):e2004433. Available from: http://dx.doi.org/10.1002/advs.202004433
2. Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin [Internet]. 2007 Spring;45(2):27–37. Available from: http://dx.doi.org/10.1097/AIA.0b013e318034194e
3. Oppenheim JJ. Cytokines: Past, present, and future. Int J Hematol [Internet]. 2001 Jul;74(1):3–8. Available from: http://dx.doi.org/10.1007/bf02982543
4. Daneshpour H, Youk H. Modeling cell-cell communication for immune systems across space and time. Curr Opin Syst Biol [Internet]. 2019 Dec;18:44–52. Available from: http://dx.doi.org/10.1016/j.coisb.2019.10.008
5. Cameron MJ, Kelvin DJ. Cytokines, chemokines and their receptors [Internet]. Georgetown, TX: Landes Bioscience; 2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6294/
6. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest [Internet]. 2008 Nov;118(11):3537–45. Available from: http://dx.doi.org/10.1172/JCI36389
7. Roberto M, Patel RR, Bajo M. Ethanol and cytokines in the central nervous system. Handb Exp Pharmacol [Internet]. 2018;248:397–431. Available from: http://dx.doi.org/10.1007/164_2017_77
8. Cheng Q, Wu H, Du Y. The roles of small-molecule inflammatory mediators in rheumatoid arthritis. Scand J Immunol [Internet]. 2021 Mar;93(3):e12982. Available from: https://doi.org/10.1111/sji.12982
9. Kiboneka A. Principals of innate and adaptive immunity. Immunity to microbes & fundamental concepts in immunology. World J Adv Res Rev [Internet]. 2021 Jun 30;10(3):188–97. Available from: http://dx.doi.org/10.30574/wjarr.2021.10.3.0271
10. Lubberts E, van den Berg WB. Cytokines in the pathogenesis of rheumatoid arthritis and collagen-induced arthritis [Internet]. Georgetown, TX: Landes Bioscience; 2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6288/
11. Furst DE, Emery P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology (Oxford) [Internet]. 2014 Sep;53(9):1560–9. Available from: https://doi.org/10.1093/rheumatology/ket414
12. Gu M, Jin Y, Gao X, Xia W, Xu T, Pan S. Novel insights into IL-37: an anti-inflammatory cytokine with emerging roles in anti-cancer process. Front Immunol [Internet]. 2023 Oct 20;14:1278521. Available from: http://dx.doi.org/10.3389/fimmu.2023.1278521
13. Moudgil KD, Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res [Internet]. 2011 Oct;31(10):695–703. Available from: http://dx.doi.org/10.1089/jir.2011.0065
14. Garlanda C, Di Ceglie I, Jaillon S. IL-1 family cytokines in inflammation and immunity. Cell Mol Immunol [Internet]. 2025 Nov;22(11):1345–62. Available from: https://doi.org/10.1038/s41423-025-01358-8
15. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood [Internet]. 1991 Dec 1;78(11):2791–808. Available from: https://doi.org/10.1182/blood.V78.11.2791.2791
16. O’Shea JJ, Gadina M, Siegel RM. Cytokines and Cytokine Receptors. In: Clinical Immunology [Internet]. Elsevier; 2019. p. 127–55.e1. Available from: https://doi.org/10.1016/B978-0-7020-6896-6.00009-0
17. Zlotnik A, Yoshie O. Chemokines. Immunity [Internet]. 2000 Feb;12(2):121–7. Available from: http://dx.doi.org/10.1016/s1074-7613(00)80165-x
18. Baggiolini M, Dewald B, Moser B. Human chemokines: An update. Annu Rev Immunol [Internet]. 1997 Apr;15(1):675–705. Available from: http://dx.doi.org/10.1146/annurev.immunol.15.1.675
19. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases: Miniperspective. J Med Chem [Internet]. 2014 Jun 26;57(12):5023–38. Available from: https://doi.org/10.1021/jm401490p
20. Kiełbowski K, Plewa P, Bratborska AW, Bakinowska E, Pawlik A. JAK inhibitors in rheumatoid arthritis: Immunomodulatory properties and clinical efficacy. Int J Mol Sci [Internet]. 2024 Jul 30;25(15):8327. Available from: http://dx.doi.org/10.3390/ijms25158327
21. Dayer JM, Oliviero F, Punzi L. A brief history of IL-1 and IL-1 Ra in rheumatology. Front Pharmacol [Internet]. 2017 May 23;8:293. Available from: http://dx.doi.org/10.3389/fphar.2017.00293
22. Vivona V, Lepore L, Bilato G, Mortara L, Lerma Barbaro D. The history of discovery of Interleukin-1: a fundamental cytokine of the innate immune response. Medicina Historica. 2024 May 23;8(1).
23. Conti P. History of cytokines: My contribution. Eur J Neurodeg Dis. 2023;(1).
24. Kristensen F, Landy M, De Weck AL. Biochemical Characterization of Lymphokines : Proceedings of the Second International Lymphokine Workshop. New York: Academic Press; 1980.
25. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A [Internet]. 1975 Sep;72(9):3666–70. Available from: http://dx.doi.org/10.1073/pnas.72.9.3666
26. Kawakami M. Discovery of tumor necrosis factor (TNF) and identification of the potential of anti-TNF antibodies in Dr. Cerami’s laboratory. Mol Med [Internet]. 2014 Dec 16;20 Suppl 1(S1):S17–9. Available from: http://dx.doi.org/10.2119/molmed.2014.00177
27. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature [Internet]. 1986;320(6063):584–8. Available from: https://doi.org/10.1038/320584a0
28. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science [Internet]. 1985 Aug 30;229(4716):869–71. Available from: http://dx.doi.org/10.1126/science.3895437
29. Brennan FM, Chantry D, Jackson AM, Maini RN, Feldmann M. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun [Internet]. 1989 Jun;2:177–86. Available from: http://dx.doi.org/10.1016/0896-8411(89)90129-7
30. Brennan F. INHIBITORY EFFECT OF TNF-alpha; ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS. Lancet [Internet]. 1989 Jul;334(8657):244–7. Available from: http://dx.doi.org/10.1016/s0140-6736(89)90430-3
31. Feldmann M, Maini RN. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) [Internet]. 1999 Nov;38 Suppl 2:3–7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10646481
32. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A [Internet]. 1992 Oct 15;89(20):9784–8. Available from: http://dx.doi.org/10.1073/pnas.89.20.9784
33. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet [Internet]. 1999 Dec;354(9194):1932–9. Available from: http://dx.doi.org/10.1016/s0140-6736(99)05246-0
34. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum [Internet]. 1993 Dec;36(12):1681–90. Available from: http://dx.doi.org/10.1002/art.1780361206
35. Dayer JM, Graham R, Russell G, Krane SM. Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science [Internet]. 1977 Jan 14;195(4274):181–3. Available from: http://dx.doi.org/10.1126/science.188134
36. Lomedico PT, Gubler U, Hellmann CP, Dukovich M, Giri JG, Pan YC, et al. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature [Internet]. 1984;312(5993):458–62. Available from: http://dx.doi.org/10.1038/312458a0
37. Dinarello CA. An update on human interleukin-1: from molecular biology to clinical relevance. J Clin Immunol [Internet]. 1985 Sep;5(5):287–97. Available from: https://doi.org/10.1007/BF00918247
38. Dinarello CA. IL‐1: Discoveries, controversies and future directions. Eur J Immunol [Internet]. 2010 Mar;40(3):599–606. Available from: http://dx.doi.org/10.1002/eji.201040319
39. Balavoine JF, De Rochemonteix B, Cruchaud A, Dayer JM. Identification of interleukin 1-like activity and inhibitor(s) in urine from a patient with acute monoblastic leukemia. Lymphokine Res. 1984;3.
40. Dayer JM. Collagenase- and PGE2-stimulating activity (interleukin-1-like) and inhibitor in urine from a patient with monocytic leukemia,” in The Physiologic, Metabolic, and Immunologic Actions of Interleukin-1. Kluger MJ, Oppenheim JJ, Powanda MC, editors. Progress in Leukocyte Biology. 1985;
41. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood [Internet]. 1991 Apr 15;77(8):1627–52. Available from: https://doi.org/10.1182/blood.V77.8.1627.1627
42. Burls A, Jobanputra P. The trials of anakinra. Lancet [Internet]. 2004;364(9437):827–8. Available from: http://dx.doi.org/10.1016/S0140-6736(04)16999-7
43. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol [Internet]. 2010 May 1;22(5):347–52. Available from: http://dx.doi.org/10.1093/intimm/dxq030
44. Ray A, Tatter SB, May LT, Sehgal PB. Activation of the human “beta 2-interferon/hepatocyte-stimulating factor/interleukin 6” promoter by cytokines, viruses, and second messenger agonists. Proc Natl Acad Sci U S A [Internet]. 1988 Sep;85(18):6701–5. Available from: http://dx.doi.org/10.1073/pnas.85.18.6701
45. Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol [Internet]. 2023 Sep 28;14:1255533. Available from: https://doi.org/10.3389/fimmu.2023.1255533
46. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet [Internet]. 2016 Oct;388(10055):2023–38. Available from: http://dx.doi.org/10.1016/s0140-6736(16)30173-8
47. Kishimoto T. INTERLEUKIN-6: From basic science to medicine - 40 years in immunology. Annu Rev Immunol [Internet]. 2005 Apr 1;23(1):1–21. Available from: http://dx.doi.org/10.1146/annurev.immunol.23.021704.115806
48. Sebba A. Tocilizumab: The first interleukin-6-receptor inhibitor. Am J Health Syst Pharm [Internet]. 2008 Aug 1;65(15):1413–8. Available from: http://dx.doi.org/10.2146/ajhp070449
49. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature [Internet]. 2003 Feb;421(6924):744–8. Available from: http://dx.doi.org/10.1038/nature01355
50. Taams LS. Interleukin-17 in rheumatoid arthritis: Trials and tribulations. J Exp Med [Internet]. 2020 Mar 2;217(3). Available from: https://doi.org/10.1084/jem.20192048
51. Miossec P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum [Internet]. 2007 Jul;56(7):2111–5. Available from: https://doi.org/10.1002/art.22733
52. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol [Internet]. 2005 Nov;6(11):1123–32. Available from: http://dx.doi.org/10.1038/ni1254
53. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol [Internet]. 2005 Nov 1;6(11):1133–41. Available from: http://dx.doi.org/10.1038/ni1261
54. Gaffen SL. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep [Internet]. 2009 Oct;11(5):365–70. Available from: http://dx.doi.org/10.1007/s11926-009-0052-y
55. Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics [Internet]. 2019 Jul 30;13:139–78. Available from: http://dx.doi.org/10.2147/BTT.S207246
56. Reimold AM. The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. Open Access Rheumatol [Internet]. 2012 May 3;4:33–47. Available from: http://dx.doi.org/10.2147/OARRR.S14569
57. Rawlings C, Choy E. The future of biological agents in the treatment of rheumatoid arthritis. Int J Clin Rheumtol [Internet]. 2014 Oct;9(5):475–86. Available from: http://dx.doi.org/10.2217/ijr.14.32
58. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis [Internet]. 2007 Nov;13(11):1323–32. Available from: http://dx.doi.org/10.1002/ibd.20225
59. Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: A systematic review and meta-analysis. J Crohns Colitis [Internet]. 2018 May 25;12(6):635–43. Available from: http://dx.doi.org/10.1093/ecco-jcc/jjy004
60. Li J, Zhang Z, Wu X, Zhou J, Meng D, Zhu P. Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis. Front Pharmacol [Internet]. 2021 Nov 1;12:746396. Available from: https://doi.org/10.3389/fphar.2021.746396
61. Wang K, Luo H, Liu L, Gao H, Song Y, Li D. Blockade of IL-1 family cytokines in the treatment of rheumatoid arthritis. Front Pharmacol [Internet]. 2025 May 30;16:1577628. Available from: https://doi.org/10.3389/fphar.2025.1577628
62. Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics [Internet]. 2008 Mar;2(1):75–82. Available from: http://dx.doi.org/10.2147/btt.s1828
63. Godse K. Secukinumab - first in class interleukin-17A inhibitor for the treatment of psoriasis. Indian J Dermatol [Internet]. 2017 Mar;62(2):195–9. Available from: http://dx.doi.org/10.4103/ijd.IJD_233_16
64. Kadagothy H, Nene S, Amulya E, Vambhurkar G, Rajalakshmi AN, Khatri DK, et al. Perspective insights of small molecules, phytoconstituents and biologics in the management of psoriasis: A focus on targeting major inflammatory cytokine pathways. Eur J Pharmacol [Internet]. 2023 May 15;947(175668):175668. Available from: https://doi.org/10.1016/j.ejphar.2023.175668
65. Sarrand J, Baglione L, Bouvy C, Soyfoo M. Bimekizumab in the treatment of axial spondyloarthritis and psoriatic arthritis: A new kid on the block. Int J Mol Sci [Internet]. 2025 Mar 5;26(5):2315. Available from: https://doi.org/10.3390/ijms26052315
66. Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs [Internet]. 2011 Nov;3(6):535–45. Available from: http://dx.doi.org/10.4161/mabs.3.6.17815
67. Pang Y, D’Cunha R, Winzenborg I, Veldman G, Pivorunas V, Wallace K. Risankizumab: Mechanism of action, clinical and translational science. Clin Transl Sci [Internet]. 2024 Jan;17(1):e13706. Available from: http://dx.doi.org/10.1111/cts.13706
68. Foti R, Amato G, Visalli E, Bosco YD, Lucia FD, Montana A, et al. Guselkumab in psoriatic arthritis: Therapeutic impact on axial and peripheral involvement-monocentric real-world evidence. J Clin Med [Internet]. 2025 May 1;14(9):3151. Available from: https://doi.org/10.3390/jcm14093151
69. Tsukazaki H, Kaito T. The role of the IL-23/IL-17 pathway in the pathogenesis of spondyloarthritis. Int J Mol Sci [Internet]. 2020 Sep 3;21(17):6401. Available from: http://dx.doi.org/10.3390/ijms21176401
70. Vecellio M, Hake VX, Davidson C, Carena MC, Wordsworth BP, Selmi C. The IL-17/IL-23 axis and its genetic contribution to psoriatic arthritis. Front Immunol [Internet]. 2020;11:596086. Available from: https://doi.org/10.3389/fimmu.2020.596086
71. Robert M, Miossec P. IL-17 in rheumatoid arthritis and precision medicine: From synovitis expression to circulating bioactive levels. Front Med (Lausanne) [Internet]. 2018;5:364. Available from: http://dx.doi.org/10.3389/fmed.2018.00364
72. Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci [Internet]. 2021 Oct 10;22(20):10922. Available from: https://doi.org/10.3390/ijms222010922
73. Zheng Y, Sun L, Jiang T, Zhang D, He D, Nie H. TNFα promotes Th17 cell differentiation through IL-6 and IL-1β produced by monocytes in rheumatoid arthritis. J Immunol Res [Internet]. 2014 Nov 11;2014:385352. Available from: http://dx.doi.org/10.1155/2014/385352
74. Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis? Curr Opin Rheumatol [Internet]. 2018 Mar;30(2):207–14. Available from: http://dx.doi.org/10.1097/BOR.0000000000000470
75. Liu D, Yu G, Yuan N, Nie D. The efficacy and safety of biologic or targeted synthetic DMARDs in rheumatoid arthritis treatment: one year of review 2024. Allergol Immunopathol (Madr) [Internet]. 2025 May 1;53(3):140–62. Available from: http://dx.doi.org/10.15586/aei.v53i3.1278
76. Malemud CJ. The role of the JAK/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis [Internet]. 2018 Jun;10(5-6):117–27. Available from: http://dx.doi.org/10.1177/1759720X18776224
77. Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: An evidence-based review on the emerging clinical data. J Inflamm Res [Internet]. 2020 Sep 14;13:519–31. Available from: http://dx.doi.org/10.2147/JIR.S219586
78. Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) [Internet]. 2019 Feb 1;58(Suppl 1):i17–26. Available from: https://doi.org/10.1093/rheumatology/key225
79. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med [Internet]. 2016 Mar 31;374(13):1243–52. Available from: http://dx.doi.org/10.1056/NEJMoa1507247
80. Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med [Internet]. 2020 Oct 15;383(16):1511–21. Available from: http://dx.doi.org/10.1056/NEJMoa2008250
81. Westhovens R, Winthrop KL, Kavanaugh A, Greenwald M, Dagna L, Cseuz R, et al. Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study. RMD Open [Internet]. 2025 Jan 30;11(1):e004857. Available from: https://doi.org/10.1136/rmdopen-2024-004857
82. Cho SK, Kim H, Song YJ, Kim HW, Nam E, Lee SS, et al. Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Korean J Intern Med [Internet]. 2023 Jul;38(4):546–56. Available from: http://dx.doi.org/10.3904/kjim.2022.369
83. Zídek Z, Anzenbacher P, Kmonícková E. Current status and challenges of cytokine pharmacology. Br J Pharmacol [Internet]. 2009 Jun;157(3):342–61. Available from: http://dx.doi.org/10.1111/j.1476-5381.2009.00206.x
84. Murer P, Neri D. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. N Biotechnol [Internet]. 2019 Sep 25;52:42–53. Available from: http://dx.doi.org/10.1016/j.nbt.2019.04.002
85. Castañeda-Hernández G, González-Ramírez R, Kay J, Scheinberg MA. Biosimilars in rheumatology: what the clinician should know. RMD Open [Internet]. 2015 May 23;1(1):e000010. Available from: http://dx.doi.org/10.1136/rmdopen-2014-000010
86. Afshari A, Karami J, Abbasifard M. Dual-targeting macromolecules: Bispecific antibodies as next-generation therapeutics for rheumatoid arthritis. Int J Biol Macromol [Internet]. 2025 Sep;322(Pt 3):146901. Available from: http://dx.doi.org/10.1016/j.ijbiomac.2025.146901
87. Ebina K, Okamoto S, Kyuuma M, Horiuchi N, Matsumoto R, Etani Y, et al. Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials. RMD Open [Internet]. 2025 Dec 11;11(4):e006218. Available from: https://doi.org/10.1136/rmdopen-2025-006218
88. Singh RP, Massachi I, Manickavel S, Singh S, Rao NP, Hasan S, et al. The role of miRNA in inflammation and autoimmunity. Autoimmun Rev [Internet]. 2013 Oct;12(12):1160–5. Available from: https://doi.org/10.1016/j.autrev.2013.07.003
89. Shaikh FS, Siegel RJ, Srivastava A, Fox DA, Ahmed S. Challenges and promise of targeting miRNA in rheumatic diseases: a computational approach to identify miRNA association with cell types, cytokines, and disease mechanisms. Front Immunol [Internet]. 2023;14:1322806. Available from: https://doi.org/10.3389/fimmu.2023.1322806
90. Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-Sanea MM, et al. Chimeric antigen receptor T-cells: An overview of concepts, applications, limitations, and proposed solutions. Front Bioeng Biotechnol [Internet]. 2022 Jun 22;10:797440. Available from: http://dx.doi.org/10.3389/fbioe.2022.797440
91. Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med [Internet]. 2022 Oct;28(10):2124–32. Available from: https://doi.org/10.1038/s41591-022-02017-5
92. Auth J, Müller F, Völkl S, Bayerl N, Distler JHW, Tur C, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol [Internet]. 2025 Feb;7(2):e83–93. Available from: http://dx.doi.org/10.1016/S2665-9913(24)00282-0
93. Dinarello CA. Historical insights into cytokines. Eur J Immunol [Internet]. 2007 Nov;37 Suppl 1(S1):S34–45. Available from: http://dx.doi.org/10.1002/eji.200737772
94. Leon L, Freites-Nuñez D, Toledano E, Candelas G, Martinez C, Rodríguez-Laguna M, et al. Primary non-response in inflammatory arthritis treated with biologics and targeted therapies in daily clinical practice. Ther Adv Musculoskelet Dis [Internet]. 2025 Mar 30;17(1759720X251325665):1759720X251325665. Available from: https://doi.org/10.1177/1759720X251325665
95. Poznyak AV, Orekhov NA, Churov AV, Starodubtseva IA, Beloyartsev DF, Kovyanova TI, et al. Interplay of rheumatoid arthritis and cardiovascular disease: Insights and prospects. SAGE Open Med [Internet]. 2025 Jul 23;13(20503121251330171):20503121251330171. Available from: http://dx.doi.org/10.1177/20503121251330171
96. Solomon DH, Peters MJL, Nurmohamed MT, Dixon W. Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis. Arthritis Rheum [Internet]. 2013 Jul;65(7):1675–83. Available from: http://dx.doi.org/10.1002/art.37975
97. Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis [Internet]. 2022 Jun;81(6):768–79. Available from: https://doi.org/10.1136/annrheumdis-2021-221733
98. Shi Y, Zhou M, Chang C, Jiang P, Wei K, Zhao J, et al. Advancing precision rheumatology: applications of machine learning for rheumatoid arthritis management. Front Immunol [Internet]. 2024 Jun 10;15:1409555. Available from: http://dx.doi.org/10.3389/fimmu.2024.1409555
99. Soyfoo M, Sarrand J. Biomarkers in rheumatoid arthritis: From traditional serology to precision medicine integration. Diagnostics (Basel) [Internet]. 2026 Jan 20;16(2). Available from: http://dx.doi.org/10.3390/diagnostics16020330
100. Hassan F, Jeries H, Daood R, Naffaa ME. Beyond monotherapy: Exploring the efficacy and safety of dual biologic strategies in rheumatic diseases. Biologics [Internet]. 2025 Nov 8;19:665–80. Available from: https://doi.org/10.2147/BTT.S565137
101. Farooq A, Trehan S, Singh G, Arora N, Mehta T, Jain P, et al. A comprehensive review of low-dose interleukin-2 (IL-2) therapy for systemic lupus erythematosus: Mechanisms, efficacy, and clinical applications. Cureus [Internet]. 2024 Sep;16(9):e68748. Available from: http://dx.doi.org/10.7759/cureus.68748
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Stoimen Dimitrov, Simona Bogdanova-Petrova, Zlatimir Kolarov (Author)